TOP
STORY

Researchers aimed to explore the effect of APRIL on human B-cell interleukin 10 (IL-10) production, in healthy subjects and in patients with rheumatoid arthritis. The IL-10 production of B-cell was greater with APRIL than with BLyS or control medium, in a dose dependent manner. [J Autoimmun]
Abstract

Scientists addressed the role of a collagen receptor, the discoidin domain receptor 1 (DDR1), in the migration of Th17 cells. They showed that the vast majority of human Th17 cells express DDR1 and that silencing DDR1 or using the blocking recombinant receptor DDR1:Fc significantly reduced their motility and invasion in three-dimensional collagen. [Oncotarget]
Full Article

Investigators showed that apoptotic tumor cell–loaded monocyte-derived dendritic cells generated in the presence of IFN-α and GM-CSF from follicular lymphoma (FL) patients, which were cultured for two weeks with autologous lymphocytes, led to Th1 response skewing, based on significantly higher levels of IFN-γ production and a remarkable increase in CD8+ and NK cell frequency, consistent with the detection of enhanced cytotoxic effector function toward autologous FL cells. [J Immunol]
Abstract

T cell receptor excision circles, Forkhead-Box-Protein P3 gene (FOXP3) methylation of regulatory T cells and relative telomere lengths were investigated in a total and subsamples of 131 patients with panic disorder as compared to 131 age- and sex-matched healthy controls in order to test for a potential dysfunction and premature aging of the immune system in anxiety disorders. [PLoS One]
Abstract

In recent years a substantial number of findings have been made in the area of immunometabolism, by which the authors mean the changes in intracellular metabolic pathways in immune cells that alter their function. They provide a brief refresher course on six of the major metabolic pathways involved, giving specific examples of how precise changes in the metabolites of these pathways shape the immune cell response. [Nat Rev Immunol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the human immunology research field.

Juno Therapeutics, Inc. announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. [Juno Therapeutics, Inc.]
Press Release

Kiadis Pharma N.V. announced that its partnership with The Leukemia & Lymphoma Society (LLS) has been strengthened with a second equity investment by LLS into the development of Kiadis Pharma’s lead product ATIR101™. [Kiadis Pharma N.V.]
Press Release

Celyad announced an exclusive license agreement with the leading Japanese immuno-oncology company, ONO Pharmaceutical Co., Ltd., for the development and commercialization of Celyad’s allogeneic NKR-2 T-cell immunotherapy in Japan, Korea and Taiwan. [Celyad]
Press Release

A paper posted to the preprint server bioRxiv, authored by senior employees at several leading science publishers (including Nature’s owner, SpringerNature), calls on journals to downplay the figure in favour of a metric that captures the range of citations that a journal’s articles attract. [Nature News]
Editorial | Article

Two weeks after the United Kingdom voted to leave the European Union, the future remains opaque. Concerns within the research community are particularly intense for those who rely on the EU for funding, or who have the right to work in the United Kingdom only because they are citizens of other EU countries. [Nature News]
Editorial

According to one of those often-quoted statistics that should be true but probably isn’t, the average number of people who read a PhD thesis all the way through is 1.6. And that includes the author. More interesting might be the average number of PhD theses that the typical scientist — and reader of Nature — has read from start to finish. [Nature News]
Editorial

U.S. and European funding agencies are launching the Human Cancer Models Initiative, which aims to give the research community tumor cells that behave more like actual human tumors. [ScienceInsider]
Editorial